Evidence map›Paper›PMID 26631610›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors.

Gregory V Kryukov, Craig M Bielski, Kaitlin Samocha, Menachem Fromer, Sara Seepo, Carleen Gentry, Benjamin Neale, Levi A Garraway, Christopher J Sweeney, Mary-Ellen Taplin and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Effects of Cytotoxic Therapies on the Sperm Genome and Epigenome.Advances in experimental medicine and biology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Gregory V KryukovBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Craig M BielskiBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Kaitlin SamochaBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts.
Menachem FromerBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts. Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York. Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.
Sara SeepoBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Carleen GentryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Benjamin NealeBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts.
Levi A GarrawayBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Christopher J SweeneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mary-Ellen TaplinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. eliezer@broadinstitute.org Mary_Taplin@dfci.harvard.edu.
Eliezer M Van AllenBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. eliezer@broadinstitute.org Mary_Taplin@dfci.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · US

Funding

Resistance to Emerging Androgen Deprivation Therapies in Prostate CancerK08CA188615 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2014 to 2017
$708k
NCI NIH HHS K08 CA188615
6 · The paper itself

Abstract

purposeCancer survivors express anxiety that chemotherapy exposure may lead to transmissible genetic damage in posttreatment children. Preclinical models suggest that chemotherapy exposure may result in considerable genomic alterations in postexposure progeny. Epidemiologic studies have not demonstrated a significant increase in congenital abnormalities in posttreatment children of cancer survivors, but the inherited genome-wide effect of chemotherapy exposure in humans is unknown. EXPERIMENTAL

designTwo testicular cancer survivors cured with chemotherapy who had children pre- and postexposure without sperm banking were identified. Familial germline whole genome sequencing (WGS) was performed for these families, and analytic methods were utilized to identify de novo alterations, including mutations, recombinations, and structural rearrangements in the pre- and postexposure offspring.

resultsNo increase in de novo germline mutations in postexposure children compared with their preexposure siblings was found. Furthermore, there were no increased short insertion/deletions, recombination frequency, or structural rearrangements in these postexposure children.

conclusionsIn two families of male cancer survivors, there was no transmissible genomic impact of significant mutagenic exposure in postexposure children. This study may provide possible reassuring evidence for patients undergoing chemotherapy who are unable to have pretreatment sperm cryopreservation. Expanded cohorts that utilize WGS to identify environmental exposure effects on the inherited genome may inform the generalizability of these results. Clin Cancer Res; 22(9); 2183-9. ©2015 AACR.

Indexed as

AdultCancer SurvivorsChild, PreschoolFemaleGerm-Line MutationHumansInfantMalePaternal ExposureRisk FactorsSpermatozoaTesticular NeoplasmsTestis

Identifiers

PMID26631610
PMCPMC4854770
OpenAlexW2181826532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.